Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2019New England Journal of MedicineOpen Access

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

KFKevin R. FlahertyUniversity of MichiganAthol U. WellsAthol U. WellsSt Thomas' HospitalVincent CottinVincent CottinUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Flaherty et al. (2019) studied this question.

synapsesocial.com/papers/69d71f4c306ad4c62a5639cchttps://doi.org/10.1056/nejmoa1908681
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease2017 · 188 citations
  2. 2Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease2009 · 602 citations
  3. 3A sharper Bonferroni procedure for multiple tests of significance1988 · 4,778 citations
  4. 4The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire2012 · 308 citations
  5. 5Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease2019 · 1,675 citations